Cargando…
Acceptability of a long‐acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076)
INTRODUCTION: High HIV incidence and low adherence to daily oral PrEP among women underscore the need for more acceptable and easier to use HIV prevention products. Global demand for injectable contraception suggests that new, long‐acting, injectable formulations could meet this need. We examine acc...
Autores principales: | Tolley, Elizabeth E, Li, Sue, Zangeneh, Sahar Z, Atujuna, Millicent, Musara, Petina, Justman, Jessica, Pathak, Subash, Bekker, Linda‐Gail, Swaminathan, Shobha, Stanton, Jill, Farrior, Jennifer, Sista, Nirupama |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813716/ https://www.ncbi.nlm.nih.gov/pubmed/31651098 http://dx.doi.org/10.1002/jia2.25408 |
Ejemplares similares
-
Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women
por: Bekker, L.G., et al.
Publicado: (2020) -
Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework
por: Amico, K. Rivet, et al.
Publicado: (2016) -
Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077
por: Tolley, Elizabeth E., et al.
Publicado: (2020) -
A Randomized-Controlled Trial of Computer-based Prevention Counseling for HIV-Positive Persons (HPTN 065)
por: McKinstry, Laura A., et al.
Publicado: (2017) -
The influence of HIV‐related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study
por: Velloza, Jennifer, et al.
Publicado: (2020)